Theratechnologies Inc Stock Price, News & Analysis

Theratechnologies (THTX) announced the resignation of Jovan Antunovic, Senior VP and Chief Commercial Officer, effective November 13, 2020. His departure comes after nearly two years with the company, where he enhanced their sales and marketing in the U.S. Paul Lévesque, CEO, will temporarily oversee operations until a new candidate is recruited. The company is focusing on finding someone with extensive U.S. experience to continue driving growth.

MONTREAL, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (THTX) announced participation in several upcoming virtual investor conferences. Management will be at B. Riley Securities' Liver Disease Therapeutics Day on October 29, 2020, featuring a panel with Dr. Christian Marsolais. Additionally, Paul Levesque will present at the 29th Annual Credit Suisse Healthcare Conference on November 10, 2020, at 8:45 a.m. ET. Webcast details will be available on the company's website one day prior to each event.

Theratechnologies has appointed Andrew Molson and Alain Trudeau as new independent members of its Board of Directors. This strategic move aims to enhance the board's expertise as the company progresses in developing tesamorelin for Nonalcoholic Steatohepatitis (NASH) and advancing its SORT1+ Technology in oncology. Ms. Dawn Svoronos, the Chair of the Board, expressed confidence in their contributions as the firm seeks to strengthen its market position.

Theratechnologies (THTX) reported financial results for Q3 FY2020, with revenues of $14,049,000, a slight decrease from $16,111,000 in Q3 FY2019. Key highlights include advancing tesamorelin for NASH treatment, restructuring sales strategies, and transitioning to EGRIFTA SV®. Despite COVID-19 challenges, the company expects to submit a Phase 3 protocol for tesamorelin to regulatory agencies soon. The net loss was $6,768,000 or $(0.09) per share compared to a loss of $1,639,000 or $(0.02) per share in Q3 FY2019.

Theratechnologies (THTX) announced that the USPTO has granted U.S. Patent No. 10,799,562, which protects the use of tesamorelin to treat Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD). This patent, expiring in 2040, is licensed exclusively from Massachusetts General Hospital. The company plans to submit a Phase 3 study protocol to the FDA and European agencies in Q4 2020, aiming to start a trial in Q1 2021 using a new formulation of tesamorelin called “F8.” Intellectual property protections will support commercialization efforts.

Theratechnologies (THTX) will report its Q3 financial results on October 15, 2020. A conference call is scheduled for 8:30 a.m. ET on the same day, hosted by CEO Paul Lévesque. The call invites participation from financial analysts and has a listen-only option for media and the public.

Details for accessing the call include a toll-free number, an international dialing option, and a webcast link. An audio replay will be available later on the same day.

MONTREAL, Sept. 30, 2020 – Theratechnologies (THTX), a biopharmaceutical company, has announced that Dr. Christian Marsolais, the Senior Vice President and Chief Medical Officer, will be presenting at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5, 2020, at 4:30 p.m. ET. Investors and others interested can access a live webcast of the presentation through the provided link, with a replay available one hour post-event.

Theratechnologies specializes in innovative therapies that address unmet medical needs, with further information available on their official website.

Theratechnologies (THTX) announced preliminary results for Q3 2020, expecting consolidated net revenues between $13.8 million and $14.2 million, down from $16.1 million in Q3 2019. The decline is attributed to the COVID-19 pandemic, one-time transitions from EGRIFTA to EGRIFTA SV, and increased rebates. As of August 31, 2020, cash reserves are projected at $27 million. CEO Paul Lévesque highlighted efforts to adapt sales strategies amidst pandemic challenges.

Theratechnologies has announced plans to initiate Phase 3 clinical trials for tesamorelin targeting Non-Alcoholic Steatohepatitis (NASH), anticipated to start in early 2021. The trial will recruit ~650 patients with fibrosis scores of 2 and 3 and a cohort of 50 HIV patients. Early positive data suggest tesamorelin reduces liver fat and fibrosis progression. The investigational formulation, known as F8, is patent-protected in the U.S. until 2033. The company aims for a supplemental Biologics License Application for a multi-dose pen injector in 2022.